Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develop… Read more
Unity Biotechnology Inc (UBX) - Net Assets
Latest net assets as of March 2025: $-205.00K USD
Based on the latest financial reports, Unity Biotechnology Inc (UBX) has net assets worth $-205.00K USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($30.35 Million) and total liabilities ($30.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-205.00K |
| % of Total Assets | -0.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | -92.16% |
| 10-Year Change | N/A |
| Growth Volatility | 46.75 |
Unity Biotechnology Inc - Net Assets Trend (2016–2024)
This chart illustrates how Unity Biotechnology Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Unity Biotechnology Inc (2016–2024)
The table below shows the annual net assets of Unity Biotechnology Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.49 Million | -77.13% |
| 2023-12-31 | $28.40 Million | -57.52% |
| 2022-12-31 | $66.85 Million | +12.22% |
| 2021-12-31 | $59.57 Million | -28.13% |
| 2020-12-31 | $82.88 Million | -31.34% |
| 2019-12-31 | $120.71 Million | -24.88% |
| 2018-12-31 | $160.69 Million | +76.89% |
| 2017-12-31 | $90.84 Million | +318.71% |
| 2016-12-31 | $-41.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Unity Biotechnology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46811900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.03% |
| Other Comprehensive Income | $15.00K | 0.23% |
| Other Components | $516.82 Million | 7958.42% |
| Total Equity | $6.49 Million | 100.00% |
Unity Biotechnology Inc Competitors by Market Cap
The table below lists competitors of Unity Biotechnology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lions Bay Capital Inc
V:LBI
|
$2.54 Million |
|
China Keli Electric Company Ltd
V:ZKL-H
|
$2.54 Million |
|
Mondo TV S.p.A
F:MJE
|
$2.54 Million |
|
Mobilia Holdings Bhd
KLSE:0229
|
$2.54 Million |
|
YB Ventures Bhd
KLSE:5048
|
$2.54 Million |
|
CCH Holdings Ltd Ordinary Shares
NASDAQ:CCHH
|
$2.54 Million |
|
1000MERCIS INH. EO-10
F:2PL
|
$2.54 Million |
|
Chase Packaging Corp
PINK:WHLT
|
$2.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Unity Biotechnology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 28,398,000 to 6,494,000, a change of -21,904,000 (-77.1%).
- Net loss of 25,990,000 reduced equity.
- Other comprehensive income increased equity by 39,000.
- Other factors increased equity by 4,047,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-25.99 Million | -400.22% |
| Other Comprehensive Income | $39.00K | +0.6% |
| Other Changes | $4.05 Million | +62.32% |
| Total Change | $- | -77.13% |
Book Value vs Market Value Analysis
This analysis compares Unity Biotechnology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.41x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-120.84 | $0.16 | x |
| 2017-12-31 | $264.28 | $0.16 | x |
| 2018-12-31 | $56.84 | $0.16 | x |
| 2019-12-31 | $27.67 | $0.16 | x |
| 2020-12-31 | $16.29 | $0.16 | x |
| 2021-12-31 | $10.67 | $0.16 | x |
| 2022-12-31 | $7.04 | $0.16 | x |
| 2023-12-31 | $1.92 | $0.16 | x |
| 2024-12-31 | $0.39 | $0.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Unity Biotechnology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -400.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 5.80x
- Recent ROE (-400.22%) is below the historical average (-110.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-26.25 Million |
| 2017 | -49.16% | -3231.26% | 0.01x | 1.12x | $-53.74 Million |
| 2018 | -47.54% | 0.00% | 0.00x | 1.13x | $-92.47 Million |
| 2019 | -62.03% | 0.00% | 0.00x | 1.25x | $-86.94 Million |
| 2020 | -110.85% | 0.00% | 0.00x | 1.89x | $-100.16 Million |
| 2021 | -100.79% | -1255.00% | 0.04x | 2.09x | $-66.00 Million |
| 2022 | -86.39% | -24469.07% | 0.00x | 1.86x | $-64.43 Million |
| 2023 | -140.36% | 0.00% | 0.00x | 2.31x | $-42.70 Million |
| 2024 | -400.22% | 0.00% | 0.00x | 5.80x | $-26.64 Million |
Industry Comparison
This section compares Unity Biotechnology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Unity Biotechnology Inc (UBX) | $-205.00K | 0.00% | N/A | $2.54 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |